BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE Drug Patent Profile

When do Bisoprolol Fumarate And Hydrochlorothiazide patents expire, and when can generic versions of Bisoprolol Fumarate And Hydrochlorothiazide launch?

Bisoprolol Fumarate And Hydrochlorothiazide is a drug marketed by Actavis Elizabeth, Apothecon, Aurobindo Pharma Ltd, Cadila, Chartwell Rx, Edenbridge Pharms, Epic Pharma Llc, Glenmark Pharms Ltd, Ivax Sub Teva Pharms, Mylan, Novitium Pharma, Teva, Unichem, Unique Pharm, and Watson Labs Teva. and is included in fifteen NDAs.

The generic ingredient in BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE is bisoprolol fumarate; hydrochlorothiazide. There are twelve drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the bisoprolol fumarate; hydrochlorothiazide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Bisoprolol Fumarate And Hydrochlorothiazide

A generic version of BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE was approved as bisoprolol fumarate; hydrochlorothiazide by EPIC PHARMA LLC on September 25^th, 2000.

Summary for BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

US Patents:	0
Applicants:	15
NDAs:	15

US Patents and Regulatory Information for BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Unique Pharm	BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE	bisoprolol fumarate; hydrochlorothiazide	TABLET;ORAL	219489-002	Mar 24, 2026	AB	RX	No	No
Novitium Pharma	BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE	bisoprolol fumarate; hydrochlorothiazide	TABLET;ORAL	215562-002	Nov 4, 2021	AB	RX	No	No
Watson Labs Teva	BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE	bisoprolol fumarate; hydrochlorothiazide	TABLET;ORAL	075469-003	Sep 25, 2000		DISCN	No	No

Investment Scenario and Fundamentals Analysis for Bisoprolol Fumarate and Hydrochlorothiazide

Last updated: February 19, 2026

What is the current market landscape for this combination drug?

Bisoprolol fumarate combined with hydrochlorothiazide targets hypertension and heart failure. The global antihypertensive drugs market was valued at approximately $60 billion in 2021 and is projected to grow at a compound annual growth rate (CAGR) of 4.5% through 2030 [1]. Fixed-dose combinations (FDCs) like bisoprolol/hydrochlorothiazide account for a growing segment, driven by increasing prevalence of cardiovascular disease and patient preference for simplified regimens.

Existing marketed products include generic formulations and brand names such as Ziac (Duramed), with substantial generic competition. The product's market share is constrained by patent expiry and existing low-cost generics.

What are the core regulatory and patent considerations?

Regulatory Clearances

• Approved by regulatory agencies including the FDA and EMA as a combination therapy for hypertension.
• Abbreviated pathways for generics under Hatch-Waxman (FDA) and EMA equivalence procedures enable faster market entry post-patent expiry.

Patent Landscape

• The original patents for bisoprolol and hydrochlorothiazide expired approximately in 2018-2020.
• New formulations or delivery systems may secure secondary patents, extending exclusivity for up to 10-12 years post-filing.
• Patent challenges are common, requiring continuous patent strategy updates.

What are the key R&D and manufacturing considerations?

Formulation and Differentiation

• Developing bioequivalent generics remains straightforward.
• Differentiating through extended-release formulations or combination with novel agents can create market niches.

Cost of Goods and Manufacturing

• Bisoprolol and hydrochlorothiazide APIs are mature and inexpensive to produce.
• Quality control and scale-up are established, lowering production costs.

What are the market entry and commercialization risks?

• Generic competition rapidly erodes market share after patent expiry.
• Price erosion driven by high-volume, low-margin sales.
• Regulatory delays or setbacks in approval processes can delay time-to-market.

What is the competitive positioning?

• Market share predominantly held by established generic manufacturers.
• Limited brand differentiation for existing formulations.
• Opportunities exist in niche markets, such as specific patient populations or combination with additional agents for resistant hypertension.

Financial outlook and investment thesis

Revenue Potential

• Estimated sales of existing generic bisoprolol/hydrochlorothiazide formulations reach billions globally.
• Margins are compressed due to intense competition, typically in the low- to mid-teens percentage.

Cost Structure and Profitability

• Entry costs primarily involve manufacturing, regulatory filings, and marketing.
• Companies with existing API supply chains can achieve high operating margins.

Strategic Opportunities

• Entry as a generic manufacturer post-patent expiry.
• Development of controlled-release or combination formulations for premium pricing.
• Licensing or partnering with established pharmaceutical firms for faster market access.

Key risks

• Rapid erosion of market share after patent expiration.
• Price competition in the generic segment.
• Stringent regulation impacting formulation approval.

Key Takeaways

• The combination drug is mature, with significant generic competition anticipated post-patent expiry.
• Opportunities exist in developing differentiated formulations and niche markets.
• Cost-efficient manufacturing combined with regulatory strategy influences competitiveness.
• Investment benefits from early entry in the generic lifecycle or innovation extensions.

FAQs

Q1: When do patents for bisoprolol fumarate and hydrochlorothiazide typically expire?
Patents for these APIs expired around 2018-2020, paving the way for generics.

Q2: Is there scope for branded or differentiated formulations?
Yes, developing extended-release or combination therapies can command premium pricing, though regulatory approval is required.

Q3: How does generic competition impact profitability?
Market entry of generics reduces prices significantly, often compressing margins to single digits.

Q4: What are the primary barriers to market entry for new players?
Patent challenges, regulatory approval processes, and establishing manufacturing scale.

Q5: What is the growth outlook for this therapeutic segment?
The overall antihypertensive market is growing at approximately 4.5% CAGR until 2030, driven by rising hypertension prevalence.

---

References

[1] Markets and Markets. (2022). Antihypertensive Drugs Market Global Forecast to 2030.